Amphastar Pharmaceuticals Inc

Research Amphastar Pharmaceuticals Inc (AMPH) on Bullrun: valuation model: 42.7% undervalued, market cap USD 913.16M, P/E 12.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerAMPH
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic
CurrencyUSD
Valuation signal42.7% undervalued
Market capUSD 913.16M
P/E12.4
Financial periodFY2025
RevenueUSD 719.89M
Revenue growth-1.7%
Net incomeUSD 98.09M
Free cash flowUSD 121.23M
Gross margin49.5%

Valuation Snapshot

Bullrun's latest valuation model marks Amphastar Pharmaceuticals Inc as 42.7% undervalued; latest market cap is USD 913.16M; P/E is 12.4.

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit;

Frequently asked questions

Is Amphastar Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Amphastar Pharmaceuticals Inc as 42.7% undervalued.

What is Amphastar Pharmaceuticals Inc's market cap?

Amphastar Pharmaceuticals Inc's market capitalization is USD 913.16M.

What is Amphastar Pharmaceuticals Inc's P/E ratio?

Amphastar Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 12.4.